Meeting
2016 Gastrointestinal Cancers Symposium
Role of MEK inhibition in improving anti-tumor responses in xenograft models of BRAF-mutated metastatic colorectal cancer.
Authors
Van Karlyle Morris II
The University of Texas MD Anderson Cancer Center, Houston, TX
Van Karlyle Morris II, Ji Wu , Liana Adam , Feng Tian , Mihai Gagea , David S. Hong , David Menter , Scott Kopetz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Translational Research
Citation
J Clin Oncol 34, 2016 (suppl 4S; abstr 265)
DOI
10.1200/jco.2016.34.4_suppl.265
Abstract #
265
Poster Bd #
D10
Abstract Disclosures
Similar Posters
Poster
2017 Gastrointestinal Cancers Symposium
Antitumor activity of panRAF inhibition in BRAF V600E metastatic colorectal cancer.
First Author: Alex Sorokin
Poster
2022 ASCO Annual Meeting
NSABP FC-11: A phase II study of neratinib (N) plus trastuzumab (T) or N plus cetuximab (C) in patients (pts) with "quadruple wild-type" metastatic colorectal cancer (mCRC) based on HER2 status.
First Author: Samuel A. Jacobs
Poster
2015 Gastrointestinal Cancers Symposium
S1406: Randomized phase II study of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz
Poster
2023 ASCO Gastrointestinal Cancers Symposium
BAYONET trial: A multicenter phase II trial of staged combination with encorafenib + binimetinib + cetuximab following encorafenib + cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer.
First Author: Yuki Matsubara